Jiangsu Nhwa Pharmaceutical (002262) Q3 2024 earnings summary

Executive summary

• Revenue for Q3 2024 reached ¥1.38 billion, up 10.07% year-over-year; net profit attributable to shareholders was ¥391 million, up 14.74% year-over-year.

• Year-to-date revenue totaled ¥4.15 billion, up 13.39% year-over-year; net profit attributable to shareholders was ¥1.02 billion, up 15.18% year-over-year.

• Excluding non-recurring items, net profit for Q3 was ¥396 million, up 16.47% year-over-year.

Financial highlights

• Basic and diluted EPS for Q3 were ¥0.39, up 13.89% year-over-year; year-to-date EPS was ¥1.01, up 14.77%.

• Operating cash flow for Q3 was ¥911 million, up 11.30% year-over-year.

• Total assets at quarter-end were ¥8.13 billion, up 10.93% from year-end 2023; shareholders' equity was ¥7.13 billion, up 10.84%.

• Non-recurring losses for Q3 were ¥5.3 million, mainly from government grants and other non-operating items.

Key financial ratios and metrics

• Weighted average ROE for Q3 was 5.64%, up 0.08 percentage points year-over-year; year-to-date ROE was 15.08%, up 0.15 points.

• Asset impairment losses decreased 35.99% year-over-year due to lower inventory write-downs.